Sou Hu Cai Jing·2025-05-26 06:40Core Viewpoint - The article highlights a significant market shift with the rise of nuclear fusion stocks amidst a broader decline in the ChiNext index, indicating a potential investment opportunity in the nuclear fusion sector driven by recent technological advancements and policy support [1][3]. Group 1: Market Dynamics - The nuclear fusion sector saw a surge with stocks like Haheng Huaton and Xue Ren Co. hitting the daily limit, with over 1.8 billion yuan in net inflow into the sector [3]. - The ChiNext index experienced a drop of 1.28%, primarily influenced by a 2.8% decline in Ningde Times, which negatively impacted the index by 0.6 percentage points [5]. - Foreign capital sold off 720 million yuan, indicating a potential shift in investment focus towards AI sectors [5]. Group 2: Key Drivers for Nuclear Fusion - A significant technological breakthrough was announced with the International Thermonuclear Experimental Reactor (ITER) set to achieve its first plasma discharge in 2026, with key performance indicators expected to exceed a Q value of 10, accelerating commercialization by five years [3][4]. - The market for nuclear fusion is projected to reach 7.8 trillion yuan if the cost of fusion power generation drops to 0.3 yuan per kilowatt-hour, with companies like Antai Technology and Western Superconducting seeing increased demand and profitability [4]. - The release of the "Nuclear Energy Technology Innovation Action Plan" by four ministries is expected to drive annual growth rates of 70% in the sector, supported by fiscal subsidies, tax incentives, and special bonds [4]. Group 3: Investment Strategies - Investors are advised to monitor the trading volume of key stocks like Xue Ren Co. and the overall sector's trading volume, which needs to exceed 15 billion yuan for sustained momentum [5]. - Signals for potential bottom-fishing in the ChiNext index include technical indicators for Ningde Times and support levels for the index [5]. - Caution is advised regarding sectors under pressure, such as innovative pharmaceuticals, and the ongoing outflow of foreign capital [5].